When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Ethyl eicosapentaenoic acid - Wikipedia

   en.wikipedia.org/wiki/Ethyl_eicosapentaenoic_acid

   Ethyl eicosapentaenoic acid (E-EPA, icosapent ethyl), sold under the brand name Vascepa among others, is a medication used to treat dyslipidemia [4] and hypertriglyceridemia. [3] It is used in combination with changes in diet in adults with hypertriglyceridemia ≥ 150 mg/dL.

3. How Much Does Vascepa Cost on Medicare? - AOL

   www.aol.com/lifestyle/much-does-vascepa-cost...

   According to Optum Perks, 30 capsules of Vascepa can cost between $91 and $99 without insurance, depending on the pharmacy you get them from. Generic versions tend to cost between $21 and $44 for ...

4. How to get a prescription without an in-person doctor visit - AOL

   www.aol.com/prescription-without-person-doctor...

   One thing you shouldn't do is buy prescription medications online without that prescription. Foreign websites offer a plethora of medications, and often claim they can sell you what you need with ...

5. Amarin Corporation - Wikipedia

   en.wikipedia.org/wiki/Amarin_Corporation

   Amarin´s sole product VASCEPA® came on the market in 2013 for triglyceride levels >=500 milligrams per deciliter. In December 2019, the FDA approved "...the use of Vascepa (icosapent ethyl) as an adjunctive (secondary) therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels (a type of fat in the blood) of 150 milligrams per deciliter or higher.

6. What does Vacepsa cost on Medicare? - AOL

   www.aol.com/lifestyle/does-vacepsa-cost-medicare...

   How much will someone pay for Vascepa on Medicare? According to Optum Perks, 30 capsules of Vascepa cost as little as $91.84, depending on the pharmacy. The generic version — icosapent ethyl ...

7. Investigators to Present New REDUCE-IT Subanalysis of VASCEPA ...

   lite.aol.com/tech/story/0022/20241111/9270771.htm

   DUBLIN and BRIDGEWATER, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that investigators will present an additional subgroup analysis from the landmark REDUCE-IT outcomes trial in patients with and without coronary artery disease (CAD) history and mechanistic data on eicosapentaenoic acid (EPA) at the American Heart Association’s Scientific ...